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a b s t r a c t
Patients with high risk myelodysplasia (HR-MDS) and acute myeloid leukaemia (AML) with chromosomal
changes involving deletion of the long arm of chromosome 5 (del5q), especially with complex karyotype,
rarely have a durable response to combination chemotherapy. In the subgroup with monosomal
karyotype there are no long term survivors (Fang et al., 2011) [1]. Recent experience indicates that the
incidence of del5q in AML is 20–30%, with only 20–25% of patients achieving complete remission (CR)
(Farag et al., 2006) [2]. Additionally, therapy has signiﬁcant toxicity, with induction death rates 20%
even in younger patients (Juliusson et al., 2009) [3]. This lack of efﬁcacy provides the clinical rationale for
combination/sequential therapy with Lenalidomide and combination chemotherapy. Dose dependent
haematological toxicity is the major safety concern with such a combination protocol. Therefore we
conducted a phase 2 study, AML Len5 (ISRCTN58492795), to assess safety, tolerability and efﬁcacy of
lenalidomide monotherapy, followed by lenalidomide with intensive chemotherapy in patients with
primary/relapsed/refractory high risk MDS or AML with abnormalities of chromosome 5.
& 2013 The Authors Published by Elsevier Ltd. .
Patients with high risk myelodysplasia (HR-MDS) and acute
myeloid leukaemia (AML) with chromosomal changes involving dele-
tion of the long arm of chromosome 5 (del5q), especially with
complex karyotype, rarely have a durable response to combination
chemotherapy. In the subgroup with monosomal karyotype there are
no long term survivors [1]. Recent experience indicates that the
incidence of del5q in AML is 20–30%, with only 20–25% of patients
achieving complete remission (CR) [2]. Additionally, therapy has
signiﬁcant toxicity, with induction death rates 20% even in younger
patients [3]. Conversely, patients with low risk MDS and del5q can
respond dramatically to lenalidomide at conventional doses [4,5].
Thus, studies have investigated lenalidomide therapy in AML/HR-
MDS. A phase 2 study of lenalidomide in HR- MDS with the del5q
abnormality (alone or with other cytogenetic abnormalities) indicated
a 20% CR rate with lenalidomide 10mg once a day, escalated to 15 mg
in suboptimally responding patients. However, all responders had
isolated del5q [6]. Subsequent studies have evaluated escalating doses
up to 50 mg daily but response rates remained 4% [7]. A phase 1
study in relapsed/refractory AML patients also indicated that lenali-
domide can be tolerated up to 50 mg daily, but there were no CR's in
the del5q population. Those that did respond had low presenting
white cell counts suggesting limited efﬁcacy as monotherapy in
proliferative disease [8] Additionally, the Nordic group had similar
ﬁndings when they assessed lenalidomide monotherapy up to 20 mg
daily in a phase 2 study for MDS/AML patients with any form of
chromosome 5 abnormality and noted no response in patients with
TP53 mutation [9]. More recently a phase 1 study of sequential
therapy with azacitidine and lenalidomide has identiﬁed an alternative
approach capable of inducing haematological improvement and
complete cytogenetic remissions, although has signiﬁcant haematolo-
gical toxicity [10].
This lack of efﬁcacy provides the clinical rationale for combina-
tion/sequential therapy with Lenalidomide and combination che-
motherapy. As already outlined dose dependent haematological
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toxicity is the major safety concern with such a combination
protocol. Therefore we conducted a phase 2 study, AML Len5
(ISRCTN58492795), to assess safety, tolerability and efﬁcacy of
lenalidomide monotherapy, followed by lenalidomide with inten-
sive chemotherapy in patients with primary/relapsed/refractory
high risk MDS or AML with abnormalities of chromosome 5.
Patients were considered eligible if they had a diagnosis of
primary/relapsed/refractory AML (as deﬁned by WHO 2008) or
high risk MDS (deﬁned as IPSS INT-2/High) with chromosome
5 cytogenetic abnormalities (including del5q) and were suitable
for intensive chemotherapy. Cytogenetic analysis was undertaken
at regional specialist cytogenetic laboratories using conventional
chromosome G-banding on bone marrow cultures. Speciﬁc FISH
analysis for del5 q was not undertaken.
The main exclusion criteria were prior use of lenalidomide or
other investigational agents within the last 4 weeks. Composite
primary endpoint was early death rate (deﬁned as death within 30
days of starting combination therapy) and survival with platelet
recovery (4100109/l) 42 days after the last dose of course one
combination therapy. If treatment was found to be safe and
acceptable, the CR rate (CR/CR with incomplete haematopoietic
recovery) was assessed at day 21 post the last cycle of combination
chemotherapy, and used to determine the sample size for the study.
A four-stage phase II non randomised trial design (Sargent) was
used to incorporate the possibility that the trial might be incon-
clusive based on the observed CR rate. Stopping rules were included
at four time points; after 10, 19, 30 and all 39 patients had completed
the ﬁrst course of combination chemotherapy. For patients recruited
with Z5% blasts, further stopping rules were speciﬁed as follows for
lenalidomide monotherapy: more than 20% having a treatment-
related death; more than 30% withdrawn due to delayed recovery
of blood counts with hypoplastic bone marrow.
All patients were recruited and consented from 6 UK leukaemia
centres. The treatment schedule was designed such that all
patients would receive an initial cycle of lenalidomide monother-
apy 10 mg daily on days 1–21 of a 28-day cycle. Remission status
was then assessed from a day 28 bone marrow.
Responses were deﬁned as; CR o5% blasts in the bone marrow
and haematopoietic recovery. CR with incomplete haematopoietic
recovery (CRi) fulﬁlling all criteria for CR except for haematopoie-
tic recovery.
Partial Response (PR) Z5% blasts in the bone marrow but
blasts having reduced by Z50% from baseline. No Response (NR)
o50% blast reduction in the bone marrow from baseline.
Patients who had presented with HR-MDS (o 5% blasts) and
had no blast excess at day 28 and who also achieved haemato-
poietic recovery, received further 28 day cycles of lenalidomide
monotherapy 10 mg daily on days 1–21. After receiving 3 cycles of
lenalidomide monotherapy, patients in remission were considered
for allogeneic stem cell transplant. If transplant were not an option
then patients would continue with maintenance lenalidomide.
Patients who presented with HR-MDS or AML (Z5% blasts)
who at day 28 had achieved a PR could receive a second cycle of
lenalidomide monotherapy. If CR or no response at day 28, then
patients progressed to combination chemotherapy with Lenalido-
mide administered at 10 mg once daily for 10 days concurrently
Fig. 1. *Includes one patient who after lenalidomide monotherapy only received a single dose of ADE but no lenalidomide as combination therapy as the patient was nil by
mouth. As recommended by the DMEC, this patient was not considered as receiving combination therapy.
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with ADE (10þ3þ5) induction therapy [Cytarabine 100 mg/m2
twice daily I.V. for 10 days, Daunorubicin 50 mg/m2 days 1,3, and
5 I.V. and Etoposide 100 mg/m2 daily days 1–5 I.V.]. If CR/PR was
achieved it was consolidated with a further course of combined
lenalidomide and ADE (8þ3þ5), followed by a course of com-
bined lenalidomide and high dose Cytarabine1.5 g/m2 twice daily
by intravenous infusion on days 1, 3 and 5 (6 doses). Patients in
remission were considered for allogeneic stem cell transplant.
Between August 2009 and May 2010, 14 patients were recruited,
median age 66 (range 40–75). The majority, 10 (71%) had AML; four
(29%) had HR-MDS. The disease was classiﬁed as; primary (9–64%),
relapsed (3–21%) and refractory (2–14%). Only two (14%) had an
isolated del5q, whilst 12 (86%) had additional chromosomal abnorm-
alities. All 14 patients received lenalidomide monotherapy. One
patient with HR-MDS had an initial PR then subsequent CR and
continues in CR on maintenance lenalidomide, 21 months since
therapy initiation. Nine patients did not respond and went on to have
the combination therapy. Therefore, following monotherapy, no
patients with blasts Z5% achieved a remission. Four patients
discontinued therapy, including three attributable to death whilst
receiving monotherapy; all 3 had Z5% blasts at diagnosis. The
overall early death rate was 21%, and 27% in patients recruited with
Z5% blasts. The patient ﬂow is summarised in Fig. 1.
Of the nine patients who received combination therapy, three
achieved CR/CRi (33%) and one patient achieved PR (11%), for an
ORR of 44%. (summarised in Table 1).
Two patients who achieved CR underwent allogeneic transplan-
tation. One died of an infection-related death in CR 16 months post
transplant; the other relapsed 17 months post transplant but
remains alive. Use of lenalidomide in close proximity to allogeneic
transplant conditioning has been linked to increased incidence of
acute GVHD [11]. However, this was not evident in the 2 patients
reported here. The other patient who achieved CRi, failed to ever
achieve sufﬁcient haematological recovery to enable further ther-
apy- eventually relapsing 301days following the achievement of CRi
prior to death. The patient who achieved PR died from neutropenic
infection, prior to being able to receive further therapy.
Adverse events were frequent in this challenging cohort of
patients. In total 9 SAEs were reported during combination
therapy, 6 of which were suspected to be related to the therapy
and included neutropenic sepsis or thrombocytopenia. All patients
experienced the anticipated haematological toxicity. Other notable
toxicities included grade 3 ALT rise (22%) and venous thrombo-
embolism (11%). This is summarised in greater detail in Table 2.
Blood product utilisation was in keeping with the recognised
requirements for such patients undergoing intensive chemother-
apy. During the ﬁrst cycle of combination chemotherapy, patients
received a median of 10 units of blood (range 4–24) and 10 units of
platelets (range 2–29). Intravenous antibiotic usage was for a
median duration of 21 days s (range 13–44). The median duration
of hospital in-patient stay was 32 nights (range 16–44).
Seven patients were evaluable for stem/progenitor cell immuno-
phenotyping at diagnosis using previously published protocols [12]
(Fig. 2). 4/7 presented with an abnormally expanded haemopoietic
stem cell (HSC) population (Lin-CD34þCD38-CD90þCD45RA-). 2/7
presented with an expanded LMPP (Lin-CD34þCD38-CD90-
CD45RAþ) and GMP (Lin-CD34þCD38þCD123þCD45RAþ)
compartment. 1/7 presented with expanded MPP (Lin-CD34þCD38-
CD90-CD45RA-) and CMP (Lin-CD34þCD38þCD123þ/lowCD45RA-)
populations. Thus, there was heterogeneous expansion of populations
with leukaemic stem cells (LSC) activity.
Sequential bone marrow samples were available for 6/7
patients. The 2/7 with an expanded HSC compartment at diagnosis
did not respond to combination therapy and there was no
signiﬁcant reduction in the size of the abnormally expanded
immunophenotypic HSC compartment. Upon achievement of
remission expanded GMP and LMPP populations were demon-
strated in the patient who responded to lenalidomide monother-
apy and continues in CR on maintenance lenalidomide. Conversely,
however, the patient who presented with low percentage of blasts,
achieved CR and remained relapse free for more than a year,
continued to have an expanded HSC compartment. Of the two
patients with an expanded GMP/LMPP compartment, one did not
respond to therapy and continued to have abnormally expanded
LMPP and GMP populations after combination therapy. The other
had an abnormally high percentage of progenitor populations
(MPP/GMP) at a point when he achieved CR by morphological
criteria. Thus, we were unable to identify a consistent stem/
progenitor proﬁle at diagnosis, or following response to therapy,
in this heterogeneous patient cohort.
It is clear that our data conﬁrm previous ﬁndings that lenali-
domide monotherapy at a dose of 10 mg daily is ineffective as
induction therapy in HR-MDS/AML patients with increased mar-
row blasts. Indeed, the consequent delay in administering cyto-
toxic chemotherapy appears detrimental to disease control and
patient outcome. In view of the unacceptable early death rate the
trial was halted for consideration of a trial protocol amendment.
An independent Data Monitoring & Ethics Committee (DMEC)
carried out a simultaneous review of data for the 9 patients who
had received combination chemotherapy. Although there were no
early deaths with the combination therapy, 7 patients had failed to
achieve platelet recovery. The formal stopping rule for the ﬁrst 10
patients was either Z5 early deaths or Z8 patients not recover-
ing platelets and surviving. One further patient received only a
Table 1
Response 21 days post last cycle of combination therapy.
ORR 4 (44%)
CR 2 (22%)
CRi 1 (11%)
PR 1 (11%)
NR 3 (33%)
PD 1 (11%)
Not evaluable 1 (11%)
Table 2
Adverse reactions during combination chemotherapy.
Grade 1+ Grade 3+
ALT, SGPT 8 (89%) 2 (22%)
AST, SGOT 1 (11%) 1 (11%)
Bilirubin 7 (78%) 1 (11%)
Diarrhoea 6 (67%) 0 (0%)
Fatigue 5 (56%) 2 (22%)
Mucositis (clinical exam) 3 (33%) 0 (0%)
Nausea 5 (56%) 1 (11%)
Neuropathy (motor) 1 (11%) 1 (11%)
Neuropathy (sensory) 1 (11%) 1 (11%)
Neutropenia 9 (100%) 9 (100%)
Thrombo-cytopenia 9 (100%) 9 (100%)
Thrombo-embolic event† 1 (11%) 1 (11%)
Vomiting 1 (11%) 1 (11%)
Grade 1+ rade 3+
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single dose of ADE and did not receive the lenalidomide, as the
patient was nil by mouth. As recommended by the DMEC, this
patient was not considered as receiving combination therapy. Note
also that this patient did not recover their platelets and survive
(died two days after the ADE because of a SAE suspected to be
related to monotherapy). Therefore, the formal stopping rule
would have been activated if this patient had been considered as
receiving combination therapy.
Patient recruitment had been challenging and well behind the
predicted rate with patients in the UK entering competing studies
due to the absence of immediate cytogenetic analysis at presenta-
tion with AML. It was, therefore, concluded that it would not be
possible to complete the study within the available time. A
decision was therefore made by the trial management group to
permanently halt recruitment rather than amend the protocol.
Although the combination therapy was deliverable, emerging
experience suggests that alternative combination strategies may
deliver similar activity with attenuated toxicity. One such example
is the combination of lenalidomide with azacitidine, for which
there are now a number of similar phase I/II studies ongoing and
the ﬁnal results are awaited [13–15].
In conclusion, lenalidomide monotherapy at a dose of 10 mg
daily is ineffective as induction therapy in HR-MDS/AML patients
with increased marrow blasts. When lenalidomide is combined
with ADE chemotherapy there is predictable and manageable
toxicity, which is not clearly greater than with combination
chemotherapy alone. Efﬁcacy is limited in this particularly adverse
patient cohort. Currently very few of these patients, even after
allogeneic transplant, achieve long-term disease free survival such
that innovative combination strategies are urgently required.
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